U.S. Life Sciences Stock News

The board of Advance Auto Parts, Inc. ( NYSE:AAP ) has announced that it will pay a dividend of $0.25 per share on the...

The board of Amcor plc ( NYSE:AMCR ) has announced that it will pay a dividend of $0.1275 per share on the 25th of...

United Community Banks, Inc.'s ( NYSE:UCB ) periodic dividend will be increasing on the 3rd of October to $0.25, with...

Navient Corporation's ( NASDAQ:NAVI ) investors are due to receive a payment of $0.16 per share on 19th of September...

NasdaqGS:FSTR 1 Year Share Price vs Fair Value Explore L.B. Foster's Fair Values from the Community and select yours...

NasdaqGM:PLBY 1 Year Share Price vs Fair Value Explore Playboy's Fair Values from the Community and select yours...

The board of Virtus Investment Partners, Inc. ( NYSE:VRTS ) has announced that it will be paying its dividend of $2.40...

NasdaqCM:BOTJ 1 Year Share Price vs Fair Value Explore Bank of the James Financial Group's Fair Values from the...

NYSE:BAP 1 Year Share Price vs Fair Value Explore Credicorp's Fair Values from the Community and select yours Credicorp...

NasdaqGS:EBON 1 Year Share Price vs Fair Value Explore Ebang International Holdings's Fair Values from the Community...

NYSE:RYAM 1 Year Share Price vs Fair Value Explore Rayonier Advanced Materials's Fair Values from the Community and...

NasdaqGS:HTLD 1 Year Share Price vs Fair Value Explore Heartland Express's Fair Values from the Community and select...

Key Insights Insiders appear to have a vested interest in JinkoSolar Holding's growth, as seen by their sizeable...

Earlier this month, Ardelyx, Inc. announced the adoption of updated company bylaws, key executive appointments, and reported strong second-quarter financial results, including a rise in revenue to US$97.66 million and increased full-year net sales guidance for IBSRELA. An interesting aspect is that Ardelyx not only grew sales but also raised revenue expectations for its lead therapy, signaling confidence in ongoing product performance despite continued net losses and pending CFO...

HCA Healthcare and its subsidiary Mission Health recently settled a federal antitrust lawsuit with local governments in Western North Carolina, agreeing to donate US$1 million to a new charity care fund and keep a regional hospital open for three additional years. This resolution addresses a legal dispute that had persisted since HCA’s acquisition of Mission Health in 2019, removing a major source of uncertainty for the company. We'll explore how closing this antitrust case could influence...

Inspire Medical Systems disclosed in the past week that its Board authorized a US$200 million share repurchase program expiring in August 2027, while also issuing updated financial guidance for 2025, lowering revenue and earnings expectations compared to previous projections. This announcement presents a complex picture, as the repurchase program may signal management's confidence, yet the revised guidance highlights near-term operational and financial challenges amid the rollout of Inspire...

Par Pacific Holdings, Inc. recently reported second quarter 2025 earnings, noting net income of US$59.46 million and basic earnings per share of US$1.18, despite sales declining to US$1.89 billion compared to a year ago. The company also completed a major share buyback during the quarter, reducing its share count by 8.58% and signaling a focus on shareholder value amid improved profitability. With these results underscoring both improved net income and capital returns, we’ll now consider...

Amplitude, Inc. recently reported its second quarter 2025 earnings, showing revenue of US$83.27 million compared to US$73.3 million a year earlier, with a net loss of US$24.67 million, and provided updated financial guidance for the rest of the year. The company’s consistent year-over-year sales growth, along with reaffirmed revenue expectations for coming quarters, underscores ongoing momentum despite continued net losses. To better understand what these results signal for Amplitude’s...

Earlier this month, Snap Inc. completed the sale of US$550 million in 6.875% senior unsecured notes due 2034, using the proceeds to repurchase portions of its outstanding convertible senior notes due 2026, 2027, and 2028 as part of a broader capital structure adjustment. An interesting aspect is that repurchased noteholders may enter the market to buy Snap Class A stock or unwind related derivatives, potentially creating upward pressure on Snap’s share price in the near term. We'll now...

In the past week, Halozyme Therapeutics reported strong second quarter results, with revenue rising to US$325.72 million and net income to US$165.16 million, and also raised full-year 2025 revenue guidance to US$1.28 billion–US$1.36 billion, citing increases in royalty revenue. Alongside robust financial performance, the company completed a share buyback totaling over US$550 million, indicating active capital management in addition to positive business fundamentals. We’ll now consider how...

Cal-Maine Foods recently announced the appointment of Melanie Boulden to its Board of Directors and Keira Lombardo as its first Chief Strategy Officer, both effective August 11, 2025. The addition of Boulden and Lombardo brings decades of leadership expertise from major food and beverage companies, expanding the company's governance and focus on long-term growth strategies. We'll explore how Lombardo's arrival as Chief Strategy Officer could shape Cal-Maine Foods' strategic priorities and...

In August 2025, Camden Property Trust was recognized for the 13th consecutive year on Fortune’s 100 Best Companies to Work For list, reflecting high employee engagement and positive workplace culture based on staff feedback. This distinction underlines the company’s ongoing focus on employee satisfaction, which can play an important role in operational consistency and retention in the residential real estate sector. Given analysts’ attention to Camden’s forward guidance, we’ll examine how...

Arcutis Biotherapeutics reported second quarter 2025 earnings showing revenue of US$81.5 million and a net loss of US$15.89 million, both improved from the prior year. Results highlight substantial operational progress, with strong revenue growth and a significant reduction in loss per share compared to the same period last year. We'll examine how these operational improvements and narrowing losses reshape Arcutis Biotherapeutics' longer-term investment outlook. AI is about to change...

Dynatrace recently reported its first quarter 2025 earnings, posting revenue of US$477.35 million and net income of US$47.96 million, both higher than a year ago, and raised its full-year 2026 revenue guidance to between US$1.97 billion and US$1.99 billion. The company also completed a share buyback of 904,609 shares during the quarter, signaling ongoing shareholder return initiatives. We'll examine how Dynatrace's raised full-year revenue guidance could influence its investment narrative...